Lolamicin is an experimental antibiotic. It targets Gram-negative bacteria without significantly affecting typical gut microbes. Lolamicin was discovered by a team led by Paul J. Hergenrother at the University of Illinois Urbana-Champaign and was first reported in 2024.
Lolamicin is an experimental antibiotic. It targets Gram-negative bacteria without significantly affecting typical gut microbes. Lolamicin was discovered by a team led by Paul J. Hergenrother at the University of Illinois Urbana-Champaign and was first reported in 2024.
In a mouse model of bacterial infection, lolamicin was found to be especially effective against Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).